Zoetis (NYSE:ZTS) Price Target Lowered to $230.00 at Barclays

Zoetis (NYSE:ZTS - Get Free Report) had its price objective cut by analysts at Barclays from $260.00 to $230.00 in a research note issued on Tuesday, Benzinga reports. The firm currently has an "overweight" rating on the stock. Barclays's target price would suggest a potential upside of 53.78% from the company's current price.

ZTS has been the subject of a number of other reports. The Goldman Sachs Group raised their target price on shares of Zoetis from $190.00 to $226.00 and gave the stock a "buy" rating in a report on Wednesday, January 17th. StockNews.com cut shares of Zoetis from a "strong-buy" rating to a "buy" rating in a report on Tuesday, February 20th. Stifel Nicolaus decreased their price objective on shares of Zoetis from $215.00 to $195.00 and set a "buy" rating for the company in a research note on Tuesday, April 2nd. Finally, Piper Sandler reaffirmed an "overweight" rating and issued a $195.00 price objective (down previously from $220.00) on shares of Zoetis in a research note on Tuesday, April 16th. Eight research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Zoetis currently has a consensus rating of "Buy" and an average target price of $218.00.

Zoetis Price Performance

Shares of NYSE ZTS traded up $4.02 during mid-day trading on Tuesday, reaching $149.56. 4,072,345 shares of the company traded hands, compared to its average volume of 3,065,285. Zoetis has a fifty-two week low of $144.80 and a fifty-two week high of $201.92. The company has a debt-to-equity ratio of 1.32, a current ratio of 3.36 and a quick ratio of 2.00. The firm has a market cap of $68.40 billion, a PE ratio of 29.50, a price-to-earnings-growth ratio of 2.24 and a beta of 0.85. The stock has a fifty day simple moving average of $173.78 and a 200-day simple moving average of $179.78.

Zoetis (NYSE:ZTS - Get Free Report) last posted its quarterly earnings data on Tuesday, February 13th. The company reported $1.24 EPS for the quarter, missing analysts' consensus estimates of $1.32 by ($0.08). Zoetis had a net margin of 27.43% and a return on equity of 51.25%. The company had revenue of $2.21 billion for the quarter, compared to analyst estimates of $2.19 billion. During the same quarter in the prior year, the business earned $1.15 EPS. Zoetis's revenue was up 8.5% compared to the same quarter last year. Equities research analysts anticipate that Zoetis will post 5.79 EPS for the current fiscal year.

Insider Activity

In other news, EVP Roxanne Lagano sold 923 shares of the business's stock in a transaction on Thursday, April 18th. The shares were sold at an average price of $151.17, for a total transaction of $139,529.91. Following the transaction, the executive vice president now directly owns 14,800 shares in the company, valued at approximately $2,237,316. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Insiders have sold a total of 2,209 shares of company stock worth $371,293 in the last ninety days. Corporate insiders own 0.15% of the company's stock.

Institutional Investors Weigh In On Zoetis

Institutional investors and hedge funds have recently modified their holdings of the business. Cary Street Partners Investment Advisory LLC lifted its stake in shares of Zoetis by 7.4% in the 3rd quarter. Cary Street Partners Investment Advisory LLC now owns 93,735 shares of the company's stock valued at $16,308,000 after purchasing an additional 6,457 shares during the last quarter. Peak Financial Advisors LLC acquired a new stake in shares of Zoetis in the 4th quarter valued at $2,776,000. BLB&B Advisors LLC lifted its stake in shares of Zoetis by 1.9% in the 3rd quarter. BLB&B Advisors LLC now owns 60,872 shares of the company's stock valued at $10,591,000 after purchasing an additional 1,107 shares during the last quarter. Ninety One UK Ltd lifted its stake in shares of Zoetis by 13.1% in the 4th quarter. Ninety One UK Ltd now owns 108,293 shares of the company's stock valued at $21,374,000 after purchasing an additional 12,537 shares during the last quarter. Finally, Raymond James Financial Services Advisors Inc. lifted its position in Zoetis by 10.9% during the 4th quarter. Raymond James Financial Services Advisors Inc. now owns 183,564 shares of the company's stock worth $36,230,000 after acquiring an additional 17,976 shares during the last quarter. Institutional investors and hedge funds own 92.80% of the company's stock.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.